BSX's acquisition of Axonics marks its entry into sacral neuromodulation and complements its Urology business.
Investors remain optimistic about Boston Scientific due to its geographical expansions and impressive acquisitions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback